Gujarat Kidney and Super Speciality Posts Q2 Consolidated Profit of Rs 6.60 Crore

Standalone PAT recorded at Rs 1.78 crore against Rs 2.30 crore in the previous year.

Reader Takeaway: Consolidated growth is driven by subsidiary expansion, while standalone operations currently face revenue and margin pressures.

What just happened

Gujarat Kidney and Super Speciality Hospital has announced its financial results for the second quarter ending September 30, 2026. The company reported a consolidated Profit After Tax (PAT) of Rs 6.60 crore, a notable increase from the Rs 2.88 crore recorded in the same period last year. Consolidated revenue from operations stood at Rs 38.09 crore compared to Rs 12.93 crore in Q2 2025.

Why this matters

The stark contrast between standalone and consolidated results highlights the company's changing business structure. While the consolidated entity benefits from its expanded portfolio, the standalone operations saw a decline in revenue from Rs 9.64 crore to Rs 8.04 crore, with profits slipping to Rs 1.78 crore from Rs 2.30 crore last year. This divergence suggests that the company's growth is now heavily reliant on its subsidiary contributions.

Auditor and Governance Update

Statutory auditors M/s. Y M Shah & Co. have completed a limited review of the results. The audit report remains unmodified for both standalone and consolidated financials, indicating no material discrepancies in the reported numbers.

What to track next

Investors should monitor the performance of individual subsidiaries and evaluate how much of the consolidated growth is sustainable. Tracking the turnaround of standalone operations will also be crucial for gauging the core business health of the hospital chain.